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A B S T R A C T
Hemophagocytic syndromes (HPS) may occur in patients of all age groups. Second-
ary HPS is more frequent than primary (familial) and is usually described in patients 
with an underlying immune disorder. This clinicopathological entity is the result of 
hemophagocytosis of hemopoietic cells due to activation of morphologically benign 
macrophages in the bone marrow. Clinical symptoms include fever, hepatospleno-
megaly, severe cytopenias, dyslipidemia, and frequent coagulopathy. The prognosis 
is dismal. Hematologic malignancies are often involved in HPS, which may present 
at any disease phase. Non-Hodgkin lymphomas and less frequently Hodgkin disease 
have been associated with HPS. Lymphoma associated hemophagocytic syndrome 
(LAHS) accounts for 40-50% of HPS where an underlying condition can be defined. 
NK/T and T peripheral lymphomas are responsible for 80% of LAHS. As far as B-cell 
lymphomas are concerned, their intravascular variant usually presents with LAHS 
(intravascular lymphomatosis), rarely encountered in Western countries and increas-
ingly reported in Asian countries. The pathogenesis of HPS is not fully understood, 
but it seems to differ between T- and B-cell lymphomas. Epstein-Barr virus is thought 
to have an important part in the pathogenetic process, since it has been detected both 
in Hodgkin and non-Hodgkin lymphomas presenting with HPS. Treatment decisions 
depend upon the underlying condition and its phase. However the most acceptable 
treatment option is currently immunochemotherapy followed by myeloablative stem 
cell transplantation.
I N T R O D U C T I O N
Hemophagocytic syndrome (HPS) is a clinically and pathologically well defined 
disease entity characterized by systemic activation of benign macrophages showing 
extensive phagocytosis of hematopoietic cells.1 Acquired HPS in adults occurs in differ-
ent occasions, including infections, autoimmune diseases, carcinomas and hematologic 
malignancies (Table 1).
Clinicopathological studies of HPS have revealed that in the majority of patients 
it is associated with hematological malignancies, mainly non-Hodgkin’s lymphoma 
and rarely Hodgkin’s disease.5 The lymphoma-associated hemophagocytic syndrome 
(LAHS) has been reported mostly in adults and can develop at presentation, dur-
ing or after treatment, at remission, relapse or transformation. Although infection 
is sometimes present, a known trigger factor cannot always be identified.1-3 As the 
clinical course of LAHS is rapidly progressive and sometimes even fatal, an ac-
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curate diagnosis and introduction of appropriate treatment 
are mandatory.2
C L I N I C A L  S y M P T O M S  
A N D  L A B O R A T O R y  F I N D I N G S
The clinical and biological features appear to be mainly 
related to HPS. They remain ill-defined because the clinical 
cases are rare and diagnosed with difficulty. Hemophagocytic 
syndrome manifestations may be masked or modified by the 
malignant process. According to the majority of reports, the 
clinical presentation is systemic with B-symptoms, prolonged 
fever, weight loss, hepatosplenomegaly and cytopenias, which 
are the cardinal symptoms of HPS. Lymphadenopathy and 
skin involvement are less frequent.2,7-11 Anemia and throm-
bocytopenia are the most common cytopenias (>80%), while 
neutropenia is less frequently observed (<50%).5,11
In most cases liver function is abnormal. Laboratory find-
ings include high levels of triglycerides, ferritin, transaminases, 
bilirubin and lactic dehydrogenase (LDH) and a low fibrino-
gen. Elevated LDH and hyperferritinemia were observed in 
>90% of the patients with LAHS.5, 11 Another valuable disease 
marker is the soluble interleukin-2 receptor (s CD25), whose 
constantly increased levels are indicative of active HPS. Fur-
thermore, impaired or absent function of NK and cytotoxic 
T-cells has been reported.1,12 In most cases, lymphomas in 
patients with LAHS were high-intermediate or high risk (90%) 
according to the international prognostic index (IPI).5
The clinical presentation of disseminated intravascular co-
agulation (DIC) depends on the histological type of lymphoma. 
Specifically, DIC was observed in all patients with intravascular 
large B cell LAHS, in almost half of the cases of T or T/NK cell 
LAHS and, finally, no coagulation abnormalities were detected 
in the majority of other type of B cell LAHS.5, 13-15 The serum 
cytokine profile of LAHS has been described. Serum levels of 
proinflammatory and anti-inflammatory cytokines, but not the 
Th2 cytokine IL-2, are elevated, thus reflecting the suggested 
“cytokine storm”.16
Since in most cases tumour mass is not prominent, bone 
marrow biopsy is usually performed because of fever, weight 
loss or cytopenia, and rarely as part of clinical staging of an 
already diagnosed lymphoma.17 Nevertheless, the main lesion 
within these biopsies was histiocytosis with hemophagocyto-
sis, whereas the neoplastic lymphoid infiltrate was equivocal 
in most cases, requiring an immunolabeling with CD20 and 
CD3 antibodies for its detection.11,17 Bone marrow infiltration 
was revealed in all intravascular B-cell lymphomas and in the 
vast majority of T,T/NK lymphomas.15,11 Limited data from 
reported cases of Hodgkin’s lymphoma and other histologi-
cal type of diffuse large B-cell lymphoma (DLBCL), revealed 
less frequent bone marrow infiltration.11,18,19 Interestingly in 
patients with LAHS, the Epstein-Barr virus (EBV) genome 
was present in most patients with T/NK cell lymphoma, but 
was detected only rarely in patients with B-cell lymphoma.20
P A T H O P H y S I O L O G y
The pathogenetic mechanism of HPS remains unclear.1 
However, the majority of reports support the concept of 
mature, activated macrophages as the main effectors in 
HPS. Dendritic, natural killer (NK) cells and cytotoxic T-
lymphocytes (CTLs) also play a key role in the pathogenesis 
HPS. These cells are normally activated by an immune stimu-
lus and mutually trigger each other. As a result the infected 
cell is killed, the antigen removed and termination of the 
immune response occurs. Hemophagocytosis results from 
poorly controlled macrophage activity.12 Although molecular 
defects have been identified in patients with hereditary HPS 
forms, this was not the case in non-hereditary HPS, including 
LAHS.21 However, depressed NK activity has been observed 
in such patients. Defective cytotoxic activity of NK and CTLs 
impairs the elimination of antigen expressing cellular targets, 
causing continuous immune activation, while preventing 
TABLe 1. Classification and Underlying Conditions of 
Hemophagocytic Syndrome (HPS)
Primary (Genetic) HPS
1. Familial hemophagocytic lymphohistiocytosis (FHL)
•	Known gene defects (perforin, munc 13-4, syntaxin 11)
•	Unknown gene defects
2. Immune deficiency syndromes
•	Chédiak-Higashi syndrome 
•	Griscelli syndrome 
•	X-linked lymphoproliferative syndrome (XLP)
Secondary (Acquired) HPS
1. Infection-associated hemophagocytic syndrome (IAHS)
•	Viruses
•	Bacteria
•	Other (fungi, leishmania) 
2. Malignancy-associated hemophagocytic syndrome 
•	Lymphoma-associated hemophagocytic syndrome (LAHS)
•	Other (multiple myeloma, acute leukemia, mycosis fungoi-
des, melanoma, hepatocellular carcinoma)
3. Autoimmune-associated hemophagocytic syndrome (macro-
phage activation syndrome)
4. Immune suppression/organ transplantation
5. Other (e.g. drug-associated)
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down-regulation of the immune response. Sustained immune 
activation leads to the clinical presentation of HPS, through 
high levels of cytokines.22-24 
It has been reported that in patients with active HPS, serum 
levels	of	interferon-γ	(IFN-γ),	interleukin	(IL)-12	and	IL-18	
are significantly higher than in patients in the remission phase 
or in healthy controls. These findings reflect the importance of 
Th1 cytokines in the HPS mechanism.23,25 Furthermore, serum 
levels of the proinflammatory cytokines tumor necrosis factor 
(ΤΝF)-α,	 IL-1β	and	IL-6	are	also	elevated	 in	patients	with	
active HPS.23,25,26 The cytokine profile seems to be somewhat 
different in patients with LAHS, depending on the underlying 
lymphoma. Ohno et al reported much higher levels of IL-6, IL-
10	and	ΤΝF-α	in	patients	with	B-LAHS	compared	to	patients	
with T-LAHS, whereas the latter presented with higher levels 
of	IFN-γ.16 These results are implicational of a difference in 
the pathogenesis of LAHS in B- and T- lymphomas.
Various studies have demonstrated a viral association 
between lymphomas and HPS. In T- and NK- cell lymphoma, 
infection by Epstein-Barr virus has been suggested to play a 
significant role in lymphomatous transformation and in mac-
rophage activation causing LAHS.11 According to emerging 
reports, presentation EBV-associated T/NK- cell lymphomas 
of particular histological types, in virus-associated hemophago-
cytic syndrome, indicates intimate relationship between EBV 
and T cells in HPS.27 Lay et al showed that infection of two 
T-cell	lines	caused	up-regulation	of	ΤΝF-α,	which	in	combi-
nation	with	IFN-γ	caused	activation	of	macrophages	both	in	
vitro and in vivo.28 In some cases of B-cell lymphomas with 
LAHS, human herpesvirus-6 (HHV-6) infection was detected 
in tumour tissue by polymerase chain reaction (PCR), but it 
was not possible to determine whether HHV-6 infected neo-
plastic or reactive cells. Although serologic data for CMV, 
HSV, varicella zoster virus (VZV), and HHV6 rarely showed 
active infection, the possibility that a viral infection other than 
EBV could up-regulate cytokines, initiate LAHS and disappear 
thereafter, could not be completely excluded.11,29,30
H I S T O P A T H O L O G I C A L  F I N D I N G S
Although lymphomas with HPS show marked heteroge-
neity as far as classification is concerned, they share some 
common clinical and biologic features that appear to be 
related to hemophagocytosis itself – the ingestion of cellular 
blood components and their precursors by macrophages.11 
The majority of HPS-associated lymphomas seem to involve 
the bone marrow at presentation. The main lesion within a 
bone marrow biopsy is histiocytosis with hemophagocytosis. 
In most cases the neoplastic lymphoid infiltrate, if present, is 
intermingled within normal hematopoietic cells, and rarely 
forms focal infiltrates.8,18,14 
The role of EBV in the pathogenesis of LAHS, although 
not thoroughly understood, is also depicted in the histopato-
logical findings. More than 80% of NK/T- lymphomas have 
been documented as EBV positive by detection of EBV en-
coded RNA (EBER) and/or latent membrane protein (LMP)-
1 in tumour cells with in situ hybridization. Recent studies 
report the presence of EBV in tumour cells of B-lymphomas 
as well, whereas 94% of Hodgkin lymphomas presenting with 
LAHS were EBV positive.6,7,10,31,32 Cytotoxic agents such as 
granzyme and T-cell intercellular antigen (TIA)-1 are always 
present in NK/T- lymphomas. Similarly, it has been reported 
that in B-cell lymphomas (mainly DLBCL) with LAHS a 
reactive T-cell population composed by activated cytotoxic 
cells (TIA1± granzyme) is present, often outnumbering the 
neoplastic B-cells.8,13,26
D I A G N O S I S
The diagnosis of HPS is based on both clinical and patho-
logical findings. Diagnostic criteria for HPS were first estab-
lished in 1991 by the Histiocyte Society and revised in 2004 as 
shown in Table 2. Other supportive evidence of HPS includes 
cerebral symptoms with moderate pleocytosis and/or elevated 
protein, transaminitis, hyperbilurubinemia, and elevated LDH.
Prolonged fever, unresponsive to antibiotics, hepatos-
plenomegaly and cytopenias, should alert the physician and 
consider the HPS in differential diagnosis. Minimal diagnostic 
requirements are a complete blood count, liver enzymes, bili-
rubin, triglycerides, ferritin and a coagulation profile including 
TABLe 2. Diagnostic Criteria for the Hemophagocytic 
Syndrome (HPS)
1. Familial disease/known genetic defect
2. Clinical and laboratory criteria (should fulfil at least 5/8) 
•	Fever
•	Splenomegaly
•	Cytopenia = at least 2 cell lines
Hemoglobin <9 g/dL
Platelets <100×109/L
Neutrophils <1×109/L
•	Hypertriglyceridemia and/or hypofibrinogenemia
Fasting triglycerides ≥265 mg/dL
Fibrinogen <150 mg/L
•	Ferritin >500 μg/L
•	Soluble CD25 ≥2400 U/ml
•	Decreased or absent NK-cell activity
•	Hemophagocytosis in bone marrow, spleen or lymph nodes
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fibrinogen. Patients suspected of HPS should receive a bone 
marrow examination and lumbar puncture at an experienced 
center. Moreover valuable diagnostic parameters are increased 
concentrations of sCD25 and decreased NK cell function.
A search for an infectious organism, such as EBV, CMV, 
HSV, adenovirus, parvovirus B19 and leishmania is recom-
mended, since most of these agents are treatable. In order to 
diagnose secondary HPS it is necessary to detect the underlying 
disorder. The patient should be screened for an underlying 
immunodeficiency, autoimmune disease and malignancies 
by appropriate studies. It should be kept in mind that HPS 
and lymphoma can be associated at initial presentation, but 
HPS can also precede the lymphoma or occur at any stage of 
treatment.
The main diagnostic problem is that, initially, HPS mas-
querades as a normal infection and too little attention is paid 
to the severity of symptoms. Much time may then be lost with 
extensive work-up for an infectious disease or with prolonged 
antibiotic treatment. In some cases, the patient’s improve-
ment with unspecific methods, such as transfusion, may be 
misleading. The fever may subside and laboratory values may 
transiently return to normal. The absence of hemaphagocyto-
sis is often the reason why the diagnosis of HPS is ruled out.
T R e A T M e N T
Hemophagocytic syndrome has a very dramatic course, 
eventually leading to multiple organ failure with high mortality. 
One-year overall survival without treatment has been reported 
5%, while death rates even after treatment approach 60%.1,5,34 
Prompt and definitive treatment is therefore required. Histori-
cally, patients with HPS have been treated with corticosteroids, 
intravenous immunoglobulin (IVIG), etoposide (VP-16), or a 
combination of these drugs. However, since there are still no 
established guidelines concerning adult HPS, and LAHS in 
particular, it remains difficult to determine exactly how each 
case should be treated. The therapeutic approach depends 
on the underlying condition and its phase, and the presence 
or not of a triggering factor, such as infection. However, the 
main treatment strategies consist of general measures and, 
more importantly, specific treatment of the underlying condi-
tion.1,34 The main treatment goals and approaches are shown 
in Table 3.
Supportive care is considered in order to avoid the risks 
related to cytopenias and disseminated intravascular coagula-
tion. Administration of antibiotics and antiviral agents controls 
or reduces the risk of opportunistic infectious complications. 
Red blood cells, platelet and fresh frozen plasma transfusion 
should be given according to laboratory and clinical findings.35 
Because of the risk of clinical deterioration, administration of 
granulocyte colony stimulating factor (GCSF) is not generally 
proposed.36
Plasmapheresis and/or exchange transfusion, have been 
described in small series and case reports. Even though the 
results were mostly encouraging, it is still questioned whether 
cytokine clearance really takes place and whether this is the 
key mechanism.37,38
Intravenous immunoglobulin (IVIG), due to its broad 
spectrum of mechanisms of action, can be effective in HPS 
treatment. IVIG inhibits complement activation, down regu-
lates T/B cell functions, neutralises superantigens and infec-
tious agents, neutralises cytokines and enhances clearance of 
pathogenetic antibodies. IVIG may be administered alone 
or in combination with other agents. Although IVIG was 
generally well tolerated and the results were relatively good, 
it is worth mentioning that in cases of malignancy associated 
HPS, sustained improvement was never actually observed.39-41
Corticosteroids have long been thought to be one of the cor-
nerstones of HPS treatment in the presence of a triggering factor. 
Life threatening hyperinflammation caused by excessive cytokines 
can be effectively treated, since corticosteroids are cytotoxic for 
lymphocytes and, therefore, inhibit cytokine expression and dif-
ferentiation of dendritic cells. Water-soluble brain-penetrating 
corticosteroids are preferred. Some authors suggest to decrease 
immunosuppression especially in patients with infection, but a 
short course of corticosteroids seems to be justified.1,35,42
TABLe 3. Treatment Goals and Approaches to Hemophago-
cytic Syndrome.
Immediate goals
1. Supportive care
•	Infection control (antibiotics/antivirals)
•	Transfusion (RBC, PLT, FFP)
2. Suppress severe hyperinflammation 
•	Corticosteroids (high dose dexamethasone)
•	Cyclosporin A 
•	IVIG
3. Kill antigen-presenting cells
•	Etoposide
Long–term goals: Treatment of underlying malignancy
1. Chemotherapy
•	Hodgkin lymphoma: ABVD
•	Non-Hodgkin lymphoma: intensive multi-agent chemother-
apy
2. Autologous SCT
3. Allogeneic SCT 
ABVD = andriamycin, bleomycin, vincristine, dacarbazine; FFP = 
fresh frozen plasma; IVIG = intravenous immunoglobulin; PLT = 
platelets; RBC = red blood cells; SCT = stem cell transplantation
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Cyclosporin A (CsA), a calcineurin inhibitor, has proven 
to be effective in controlling various cytokine-related patho-
logical conditions, as it affects T-lymphocyte activation, and 
macrophage and dendritic cell function.43 It can be a key 
drug in HPS induction and maintenance therapy leading to 
reduction of hypercytokinemia. It has also been reported that 
introducing CsA treatment effectively supports neutrophil re-
covery during the acute phase of HPS in severely neutropenic 
patients.36,44-46 Its importance in LAHS treatment is implied by 
the fact that CsA, as single agent therapy, is effective in T-cell 
lymphoprolipherative syndromes.40,41 Administration of CsA 
depends on an appropriate renal function, while hepatic and 
central nervous system side effects may mimic HPS manifesta-
tions. Moreover, there is no consensus regarding when to start 
and when to terminate treatment with CsA.42
Etoposide (VP-16) was introduced to the treatment of 
HPS in the 80’s. It is highly active against monocytic and 
histiocytic diseases. Its mode of action in HPS seems to be 
the killing of pathogen-infected antigen-presenting cells in 
order to reduce the stimulus for the ongoing but ineffective 
activation of cytotoxic cells. Patients with lymphoprolifera-
tive disorders and LAHS may benefit from the combination 
of VP-16 and CsA, since it induces apoptosis in NK/T cell 
lymphoma cell lines.50 In this combination neutopenia result-
ing from VP-16 is attenuated by the concurrent use of CsA. 
Long-term low dose oral VP-16 has been suggested to be a 
safe and effective option.51,52 Even so, careful follow-up of 
patients treated with VP-16 is required, because VP-16 has 
been associated with secondary malignancies, most frequently 
treatment related secondary acute myeloid leukemia and 
myelodysplastic syndrome.53 
In the international HLA-94 protocol treatment consisted 
of an initial 8-week period of dexamethasone (DXM) and VP-
16, followed by maintenance with CsA and alternating pulses 
of VP-16 and DXM. Currently, the most common treatment 
for HPS is a core combination of corticosteroids and VP-16, as 
suggested in the previously mentioned protocol. This therapy 
aims to eventually eradicate the proliferating T and NK cells, 
and activated macrophages, thus resolving the HPS.50
Antithymocyte globulin, especially when combined with 
corticosteroids, might be equivalent to VP-16 in situations 
with refractory disease, but its significant side effects, i.e. al-
lergic reactions and severe immunosuppression limit its use 
in clinical practice.49 Alemtuzumab and 2CdA have also been 
used for HPS therapy with no definite results.
Lymphoma associated hemophagocytic syndromes are re-
fractory or respond temporarily to immunosuppressive thera-
peutic approaches. In this setting, treatment of the underlying 
lymphoma is imperative. Intensive multi-agent chemotherapy 
is the treatment of choice. However, the standard regimen 
CHOP, consisting of andriamycin, cyclophosphamide, vin-
cristine and prednisone, is not effective enough in more than 
70% of cases with NHL associated with HPS. Most patients 
present a transient response and eventually relapse.5 Second 
line chemotherapy is then required preferably followed by au-
tologous or allogeneic stem cell transplantation (SCT). Second 
line regimens usually include high-dose cytosine arabinoside, 
vincristine, VP-16, cyclophosphamide, cisplatin, and steroids. 
L-asparaginase based chemotherapy has proven to be effective 
in aggressive T/NK lymphoma, and methotrexate based regi-
mens are a good alternative for intravascular and other B-cell 
lymphomas. A combination of CsA with multi-agent chemo-
therapy is considered to be the most effective therapy and in 
some cases even good enough for a cure without SCT.34,42,54,55
Since only a few cases of Hodgkin’s lymphoma presenting 
with hemophagocytic syndrome have been published, the data 
are rather scarce. However, these patients seem to respond bet-
ter to standard therapy with ABVD (andriamycin, bleomycin, 
vincristine, dacarbazine). In case of relapse, second-line treat-
ment followed by autologous or allogenic SCT is imperative.
Myeloablative chemotherapy and subsequent SCT are 
currently the gold standard of treatment regimens for therapy 
resistant non familial HPS and LAHS. Autologous SCT has 
been used as part of front line therapy in patients with ag-
gressive lymphomas, such as those associated with HPS, but 
its role on survival prolongation is still under investigation. 
The BEAM (BCNU-carmustine, etoposide, cytarabine, and 
melphalan) chemotherapy scheme is the most commonly used 
conditioning regimen. Although the results were improved 
compared to those after chemotherapy only, relapse rates 
remain relatively high and overall survival does not exceed 
30% in two years.34,56-58
Allogeneic SCT is theoretically preferred over autolo-
gous SCT, because the stem cell source in this case is tumour 
free, and the possibility of a graft versus lymphoma effect is 
present.59 In 2002, Henter et al first reported the results of 
a prospective multicenter therapeutic trial for patients with 
HPS. Induction therapy consisted of combination chemo/
immunotherapy to achieve remission and SCT followed in 
order to achieve a definitive cure. Overall, 2-year survival was 
reported as 55%, with most fatalities occurring either early 
after diagnosis or early after transplantation, mainly due to 
relapse or infection.60 A busulfan/fludarabine/VP-16 based 
regimen is commonly used for patients with HPS, although 
total body irradiation-based regimens have also been em-
ployed in refractory disease. However, in cases of underlying 
lymphoma, a combination containing alemtuzumab may be 
more effective. Primary non-engraftment occurred 10-25% of 
patients who received myeloablative conditioning therapy. The 
development of secondary malignancies, i.e. myelodysplastic 
syndrome/acute myeloid leukemia was a major problem, but 
the researchers conclude that this risk is relatively limited and 
acceptable considering the positive therapeutic effects of the 
combination of chemo/immunotherapy with SCT.60-63
The causes of death were multifactorial, including infec-
tion, hemorrhage, organ failure and graft versus host disease 
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(GVHD), while the occurrence of veno-occlusive disease and 
interstitial pneumonia was remarkable as well. As expected, 
HLA-matched sibling donors were associated with higher 
survival rates, compared to matched unrelated donors, hap-
loidentical and cord blood stem cells.59 Data from these series 
also suggest that both SCT complications and outcomes are 
affected by the HPS disease status. In cases of active disease 
at the time of transplant overall survival was found to be de-
creased. Furthermore, Horne et al correlated active disease 
at the time of transplant with primary graft failure. They also 
reported that, independent of the clinical status at the time of 
transplantation, patients whose disease was more refractory 
to initial medical therapy had worse overall survival rates 
after SCT.64,65
A reduced-intensity conditioning (RIC) regimen can 
reduce treatment related mortality, while the graft versus 
lymphoma effect is preserved. Marsh et al recently published 
the results of SCT after a reduced-intensity preparative regi-
men consisting of alemtuzumab, fludarabine, and melphalan. 
In this report, even though infection rates were not different 
compared to those of myeloablative series, no non-infectious 
complications were documented. However, a high incidence of 
mixed chimerism among the RIC patients was observed.61,67,68 
There are conflicting data concerning the feasibility of RIC 
transplantation in patients with LAHS. Some studies dem-
onstrate no preservation of graft versus lymphoma (GVL) 
effect after RIC-SCT in patients with aggressive lymphomas, 
and others show encouraging results in terms of event-free 
survival. Consequently, a myeloablative regimen should be 
the standard of care for the time being.
Overall, with regard to the therapeutic approach, prompt 
and effective therapy is imperative. It is not an easy decision 
to treat a febrile and pancytopenic patient with aggressive 
immuno/chemotherapy. However, if hyperinflammation is not 
controlled, the patient will definitely succumb to infection or 
multiple organ failure.
C O N C L U S I O N
In patients with prolonged fever, unresponsive to antibi-
otics, marked cytopenias, coagulopathy and hepatospleno-
megaly, the differential diagnosis of HPS should be considered. 
The most common cause of acquired HPS is LAHS, most 
cases being associated with T-cell or NK/T-cell lymphoma. 
The pathogenetic procedure leading to this condition remains 
unclear, but it has been demonstrated that LAHS is highly 
aggressive, having only transient response to comprehensive 
therapy and very dismal prognosis. Consequently, rapid 
therapeutic decisions need to be made. In absence of specific 
guidelines for the treatment of patients with LAHS, immuno/
chemotherapy followed by autologous or allogeneic SCT is 
considered to be the preferred approach. 
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